Something to note: oral treatment & if successful:
https://www.google.com.au/amp/s/www.nytimes.com/2021/10/17/health/covid-treatment-access-molnupiravir.amp.html
3% vaccination rate across Africa, quoted in this article. That’s appalling. Oral treatments for COVID-19 should know no boundaries. They don’t need cold-chain nor expense or expertise to hospitals administering IV expensive MABS. Other Drug companies (ie Merck) will allow out-licensing with cheaper cost to Govts/patients for oral antivirals +/- WHO support.
https://www.reuters.com/business/healthcare-pharmaceuticals/aurobindo-pharma-stop-molnupiravir-trial-moderate-covid-19-patients-2021-10-08/
Interesting article above on Molnupiravir trials in India.
GLTAH
Something to note: oral treatment & if...
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
60.0¢ |
Change
-0.010(1.64%) |
Mkt cap ! $335.3M | |||
| Open | High | Low | Value | Volume |
| 60.5¢ | 61.0¢ | 59.5¢ | $499.4K | 829.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 59573 | 59.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 60.5¢ | 35003 | 3 |
View Market Depth
| Last trade - 10.23am 21/06/2024 (20 minute delay) ? |
| DXB (ASX) Chart |